Human Papillomavirus and the use of nanoparticles for immunotherapy in HPV-related cancer: A review

Michael Jakob Rupar; Pawel Golusinski; Wojciech Golusinski; Michal M Masternak

doi:10.1016/j.rpor.2019.08.006

Human Papillomavirus and the use of nanoparticles for immunotherapy in HPV-related cancer: A review

Rep Pract Oncol Radiother. 2019 Nov-Dec;24(6):544-550. doi: 10.1016/j.rpor.2019.08.006. Epub 2019 Sep 25.

Authors

Michael Jakob Rupar¹, Pawel Golusinski^{2

3

4}, Wojciech Golusinski⁴, Michal M Masternak^{1

4}

Affiliations

¹ Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, 6900 Lake Nona Blvd., Orlando, FL 32827, USA.
² Department of Otorhinolaryngology and Maxillofacial Surgery, University of Zielona Gora, Zielona Gora, Poland.
³ Head and Neck Cancer Biology Lab, Department of Biology and Environmental Sciences, Poznan University of Medical Sciences, Poznan, Poland.
⁴ Department of Head and Neck Surgery, Poznan University of Medical Sciences, The Greater Poland Cancer Centre, Poznan, Poland.

Abstract

Human Papillomavirus (HPV) remains one of the most commonly contracted sexually transmitted diseases around the world. There are a multitude of HPV types, some of which may never present any symptoms. Others, however, are considered high-risk types, which increase the chance of the person infected to develop cancer. In recent years, the utilization of nanotechnology has allowed researchers to employ and explore the use of nanoparticles in immunotherapies. The new nanoparticle frontier has opened many doors in this area of research as a form of prevention, diagnosis, and treatment in cancers resulting from HPV. This review will provide a brief background of HPV, its relationship to head and neck cancer (HNC) and present some insight into the field of immunotherapeutic nanoparticles.

Keywords: Cancer; HNC; HPV; Immunotherapy; Nanoparticle.

Publication types

Review